reports
Aeglea Biotherapeutics Inc: 1 director
A director at Aeglea Biotherapeutics Inc maiden bought 90,000 shares at 0.561USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
- Jonathan Moreland
HNRG HALLADOR ENERGY CO.
CTSO CYTOSORBENTS
AAT AMERICAN ASSETS TRUST INC.
SCVL SHOE CARNIVAL INC.
AGLE AEGLEA BIOTHERAPEUTICS
FSK FS KKR CAPITAL CORP
KFS KINGSWAY FINANCIAL SERVICES
TELA TELA BIO
VOXX AUDIOVOX CORPORATION
U UNITY SOFTWARE INC.
PTVE PACTIV EVERGREEN
ABNB AIRBNB INC. CLASS A
ORGN ORIGIN MATERIALS
SOFI INC.
ROVR SOFI TECHNOLOGIES INC
PAY ROVER GROUP INC
OLO PAYMENTUS HLDGS INC
DB CRUDE OIL LONG EXCHANGE TRADED NOTES DUE JUNE 1 2038
- Jonathan Moreland
MYE MYERS INDUSTRIES INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
MACK MERRIMACK PHARMACEUTICALS INC
KW KENNEDY-WILSON HOLDINGS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
HZN HORIZON GLOBAL CORP.
EXLS EXLSERVICE HOLDINGS INC.
CROX CROCS INC.
COTY COTY INC. CLASS A
COMM COMMSCOPE HOLDING CO. INC.
ANIK ANIKA THERAPEUTICS INC.
AAT AMERICAN ASSETS TRUST INC.
FRBK REPUBLIC FIRST BANCORP INC.
CLOV CLOVER PAKISTAN LTD.
ELY CALLAWAY GOLF COMPANY
IGR CBRE CLARION GLOBAL REAL ESTAT
USFD US FOODS HOLDING CORP.
WINA WINMARK CORP.
AGLE AEGLEA BIOTHERAPEUTICS
OCX ONCOCYTE
JHG JANUS HENDERSON GROUP PLC
YEXT YEXT
APPN APPIAN
SNCR SYNCHRONOSS TECHNOLOGIES
DOCU INC.
BBIO DOCUSIGN INC.
BW BRIDGEBIO PHARMA
AXLA BABCOCK & WILCOX ENTERPRISES
PWFL AXCELLA HEALTH
BRP POWERFLEET INC
FRG BRP GROUP
AHCO FRANCHISE GROUP
HGEN ADAPTHEALTH
BLI HUMANIGEN
KNTE INC
SKLZ BERKELEY LIGHTS
INDT INC.
LSEA KINNATE BIOPHARMA
AIRC SKILLZ INC (A)
KBNT INDUS REALTY TRUST INC
NOTV LANDSEA HOMES CORP (A)
PFX APARTMENT INCOME REIT
PCOR KUBIENT
DUOL INOTIV
SOFI INC.
VWE PHENIXFIN CORP
ROVR PROCORE TECHNOLOGIES
INC.
DUOLINGO
INC.
SOFI TECHNOLOGIES INC
VINTAGE WINE ESTATES INC
ROVER METALS CORP
- Jonathan Moreland
MYE MYERS INDUSTRIES INC.
KW KENNEDY-WILSON HOLDINGS INC.
EXLS EXLSERVICE HOLDINGS INC.
BNED BARNES & NOBLE EDUCATION INC.
IGR CBRE CLARION GLOBAL REAL ESTAT
ARDC ARES DYNAMIC CREDIT ALLOCATION
PMD PSYCHEMEDICS CORP.
AGLE AEGLEA BIOTHERAPEUTICS
AXLA AXCELLA HEALTH
LSEA LANDSEA HOMES CORP (A)
PFX PHENIXFIN CORP
SOFI SOFI TECHNOLOGIES INC
- Jonathan Moreland
SKYW SKYWEST INC
OPK OPKO HEALTH INC.
MACK MERRIMACK PHARMACEUTICALS INC
IVC INVACARE CORPORATION
HMTV HEMISPHERE MEDIA GROUP
EXLS EXLSERVICE HOLDINGS INC.
CROX CROCS INC.
COMM COMMSCOPE HOLDING CO. INC.
BBW BUILD-A-BEAR WORKSHOP
ANIK ANIKA THERAPEUTICS INC.
ELY CALLAWAY GOLF COMPANY
USFD US FOODS HOLDING CORP.
AGLE AEGLEA BIOTHERAPEUTICS
VERI VERITONE INC.
JHG JANUS HENDERSON GROUP PLC
RBBN RIBBON COMMUNICATIONS
FLNT FLUENT INC
SNCR SYNCHRONOSS TECHNOLOGIES
FSK INC.
BRP FS KKR CAPITAL CORP
GCI BRP GROUP
AHCO GANNETT CO. INC.
HGEN ADAPTHEALTH
CMTV HUMANIGEN
BLI INC
KNTE COMMUNITY BANCORP INC. VT
SKLZ BERKELEY LIGHTS
LSEA INC.
RAND KINNATE BIOPHARMA
AIRC SKILLZ INC (A)
SLNG LANDSEA HOMES CORP (A)
KBNT RAND CAPITAL
ALIT APARTMENT INCOME REIT
DUOL STABILIS ENERGY
RXRX INC.
CLOV KUBIENT
INDI ALIGHT
CELU INC. / DELAWARE
DUOLINGO
INC.
RECURSION PHARMACEUTICALS
INC.
CLOVER HEALTH INV CORP
INDIE SEMICONDUCTOR INC
GX ACQUISITION CORP.
- Jonathan Moreland
WIRE ENCORE WIRE CORPORATION
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
STWD STARWOOD PROPERTY TRUST INC.
PRGO PERRIGO CO. PLC
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OEC ORION ENGINEERED CARBONS SA
MTDR MATADOR RESOURCES COMPANY
HQY HEALTHEQUITY INC
GOGO GOGO INC.
FOE FERRO CORPORATION
EEFT EURONET WORLDWIDE INC.
CUTR CUTERA INC.
CHGG CHEGG INC.
BCOR BLUCORA INC.
AAT AMERICAN ASSETS TRUST INC.
NAUT NAUTILUS MARINE SERVICES
ET ENERGY TRANSFER L.P.
INBK FIRST INTERNET BANCORP
AGLE AEGLEA BIOTHERAPEUTICS
CLF CLIFFS NATURAL RESOURCES INC.
PETQ PETIQ INC. CLASS A
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
LAZY LAZYDAYS HOLDINGS
APTX APTINYX
PSN PARSONS
MRBK MERIDIAN
BRBR BELLRING BRANDS
XAIR BEYOND AIR
CXDO CREXENDO
AHCO ADAPTHEALTH
GLXZ GALAXY GAMING INC
RC GRUPO RADIO CENTRO S.A.B. DE C.V.
ASAN ASANA
SSSS SUTTER ROCK CAPITAL CORP.
MPLN MULTIPLAN CORP CLASS A
INDT INDUS REALTY TRUST INC
BTRS BTRS HOLDINGS INC (A)
OEG ORBITAL ENERGY GROUP
TSHA TAYSHA GENE THERAPIES
PFX PHENIXFIN CORP
LAZR LUMINAR TECHNOLOGIES INC (A)
GOEV CANOO INC
CANO CANO HEALTH
NIHK INC.
VWE NIGHTHAWK SYSTEMS
ARC VINTAGE WINE ESTATES INC
FXLV AMERICAN REPROGRAPHICS CO.
JOBY F45 TRAINING HLDGS INC
MACQ JOBY AVIATION INC
MCAP ACQUISITION CORP
- Jonathan Moreland
SIX SIX FLAGS ENTERTAINMENT CORPORATION
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SYNL SYNALLOY CORP.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PRGO PERRIGO CO. PLC
OCUL OCULAR THERAPEUTIX
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
HQY HEALTHEQUITY INC
CUTR CUTERA INC.
CHGG CHEGG INC.
CAPL CROSSAMERICA PARTNERS LP
BNED BARNES & NOBLE EDUCATION INC.
BCOR BLUCORA INC.
APAM ARTISAN PARTNERS ASSET MANAGEMENT INC. CLASS A
ET ENERGY TRANSFER L.P.
EVBG EVERBRIDGE INC.
AGLE AEGLEA BIOTHERAPEUTICS
CDZI CADIZ INC.
AXON AXON ENTERPRISE INC
ATUS ALTICE USA INC. CLASS A
CLF CLIFFS NATURAL RESOURCES INC.
PETQ PETIQ INC. CLASS A
EYEN EYENOVIA INC
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
CSSE CHICKEN SOUP FOR THE SOUL ENTERTAINMENT INC
EVRG EVERGY
EVER INC.
SAFE EVERQUOTE
PSN SAFEHOLD INC.
VERO PARSONS
CXDO VENUS CONCEPT
GLXZ CREXENDO
ALTG GALAXY GAMING INC
AOUT ALTA EQUIPMENT GROUP INC.
ATCX AMERICAN OUTDOOR BRANDS
ASAN INC.
SSSS ATLAS TECHNICAL CONSULTANTS INC (A)
ATNF ASANA
OEG SUTTER ROCK CAPITAL CORP.
KBNT 180 LIFE SCIENCES CORP
PHX ORBITAL ENERGY GROUP
LAZR KUBIENT
GOEV PANHANDLE OIL AND GAS INC
KPLT LUMINAR TECHNOLOGIES INC (A)
VWE CANOO INC
ARC KATAPULT HOLDINGS
JOBY INC.
APTO VINTAGE WINE ESTATES INC
AMERICAN REPROGRAPHICS CO.
JOBY AVIATION INC
APTOSE BIOSCIENCES INC.
- Jonathan Moreland
GOGO GOGO INC.
CHGG CHEGG INC.
CAPL CROSSAMERICA PARTNERS LP
ET ENERGY TRANSFER L.P.
GBLI GLOBAL INDEMNITY PLC
AGLE AEGLEA BIOTHERAPEUTICS
AXON AXON ENTERPRISE INC
SVRA SAVARA
CLF CLIFFS NATURAL RESOURCES INC.
FPAY FLEXSHOPPER
SAFE SAFEHOLD INC.
LMPX LMP AUTOMOTIVE HOLDINGS
AOUT INC.
ACET AMERICAN OUTDOOR BRANDS
ATNF INC.
HIPO ADICET BIO INC
OEG 180 LIFE SCIENCES CORP
XMTR HIPPO VALLEY ESTATES LTD
KPLT ORBITAL ENERGY GROUP
FHTX XOMETRY
NIHK INC.
VWE KATAPULT HOLDINGS
INC.
FOGHORN THERAPEUTICS
NIGHTHAWK SYSTEMS
VINTAGE WINE ESTATES INC
Aeglea BioTherapeutics to Participate in September Investment Conferen...
Aeglea BioTherapeutics to Participate in September Investment Conferences AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in three investor conferences in September 2020, including presenting at the H.C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020. Conference Presentation Details Conference: H.C...
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 20...
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020 AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020. Presentation Details Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of pati...
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results a...
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177 for the Treatment of Homocystinuria AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today r...
Aeglea BioTherapeutics to Present at BIO Digital 2020
Aeglea BioTherapeutics to Present at BIO Digital 2020 AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will provide a corporate overview at BIO Digital being held virtually June 8-12, 2020. Presentation Details Date: June 8-12, 2020 Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer Location: The presentation will be avai...
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting ...
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020 AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. As pre...
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Pat...
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with Previously Reported Results AUSTIN, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions f...
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzil...
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology AUSTIN, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will present a new 56 week analysis on patients who have been treated with pegzilarginase from the completed Phase 1/2 clinical trial and the ongoin...
- Jonathan Moreland
GEO GEO GROUP INC. (THE)
1A80 ACCELERATE DIAGNOSTICS INC.
ITW ILLINOIS TOOL WORKS INC.
TDG TRANSDIGM GROUP INCORPORATED
STFC STATE AUTO FINANCIAL CORP.
PCH POTLATCHDELTIC CORPORATION
OPK OPKO HEALTH INC.
NWBI NORTHWEST BANCSHARES INC.
NLY ANNALY CAPITAL MANAGEMENT INC.
NFBK NORTHFIELD BANCORP INC.
DLY LYONDELLBASELL INDUSTRIES NV
JRVR JAMES RIVER GROUP HOLDINGS LTD
HMST HOMESTREET INC.
F FORD MOTOR COMPANY
EIG EMPLOYERS HOLDINGS INC.
CHCT COMMUNITY HEALTHCARE TRUST INCORPORATED
CCNE CNB FINANCIAL CORP. (PENNSYLVANIA)
CB CHUBB LIMITED
CALX CALIX NETWORKS
BYD BOYD GAMING CORPORATION
BPFH BOSTON PRIVATE FINANCIAL HOLDINGS INC.
BOCH BANK OF COMMERCE HOLDINGS
AMG AFFILIATED MANAGERS GROUP INC.
AHH ARMADA HOFFLER PROPERTIES INC.
AIG AMERICAN INTERNATIONAL GROUP INC.
TRST TRUSTCO BANK CORP.
PMBC PACIFIC MERCANTILE BANCORP
MLM MARTIN MARIETTA MATERIALS INC.
CFR CULLEN/FROST BANKERS INC.
CMO CAPSTEAD MORTGAGE CORPORATION
MLHR HERMAN MILLER INC.
UNVR UNIVAR SOLUTIONS INC.
GRA W R GRACE & CO
CNBKA CENTURY BANCORP INC. CL A
FBK FB FINANCIAL CORPORATION
SVBI SEVERN BANCORP INC.
AGLE AEGLEA BIOTHERAPEUTICS
CADE CADENCE BANCORPORATION
MYOV MYOVANT SCIENCE
CATC CAMBRIDGE BANCORP
UNTY UNITY BANCORP INC.
SMPL SIMPLY GOOD FOODS CO
RESI FRONT YARD RESIDENTIAL CORP. CLASS B
CBTX CBTX
CHMG CHEMUNG FINANCIAL CORP.
STXB SPIRIT OF TEXAS BANCSHARES
BBDC BARINGS BDC INC.
NBSE NEUBASE THERAPEUTICS
HBT HBT FINANCIAL
BQH BLACKROCK NEW YORK MUNICIPAL BOND TRUST
VOXX AUDIOVOX CORPORATION
FENC FENNEC PHARMACEUTICALS INC.
CFFA CF FINANCE ACQUISITION
AGNC AMERICAN CAPITAL AGENCY CORP.
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results an...
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clinical Trial in Homocystinuria Initiation AUSTIN, Texas, May 07, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its ...
- Jonathan Moreland
FFIN FIRST FINANCIAL BANKSHARES INC
F FORD MOTOR COMPANY
CALX CALIX NETWORKS
AMG AFFILIATED MANAGERS GROUP INC.
TPB TURNING POINT BRANDS
SRCE 1ST SOURCE CORP.
SVBI SEVERN BANCORP INC.
AGLE AEGLEA BIOTHERAPEUTICS
RESI FRONT YARD RESIDENTIAL CORP. CLASS B
PFIS PEOPLES FINANCIAL SERVICES CORP.
NBSE NEUBASE THERAPEUTICS
FENC FENNEC PHARMACEUTICALS INC.
CFFA CF FINANCE ACQUISITION
Aeglea BioTherapeutics Announces Closing of Public Offering and Full E...
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering of 15,442,303 shares of its common stock at a public offering price of $4.75 per share, which includes the exercise in full of the underwriters’ option to purchase 3,789,47...
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offeri...
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten public offering of 11,652,830 shares of its common stock at a price to the public of $4.75 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warrants to purchase up to an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.